Enhanced Oncolytic Viral Vaccine

SK2013-029

Summary of Invention

This is a cancer vaccine in which the anti-tumor effect of an oncolytic virus (Newcastle Disease Virus or NDV) is enhanced using a co-stimulatory ligand.

NDV is a contagious avian disease that targets and destroys tumor cells in humans. NDV, however, has several limitations. It has been found to be successful locally but not systemically, often resulting in ineffective treatment of metastatic tumor sites. In addition, anti-viral immunity can develop quickly.

Co-stimulatory ligands such as OX-40L, 4-1BBL, GITRL, CD40L, ICOSL and anti-CD28 single chain are essential for T-cell activation and proliferation. By modifying NDV to express these co-stimulatory ligands, a strong, systemic but targeted anti-tumor effect is elicited, leading to effective tumor suppression.

When used in combination with anti-CTLA-4 therapy, NDV-expressing ICOSL was found to be highly effective in a mouse model of melanoma, which led to long-term animal survival as well as protection against tumor re-challenge.

Advantages

  • Targeted therapy
  • Enhanced immune response to an oncolytic virus
  • Systemic administration possible

Market Opportunities

The US cancer vaccine market was estimated to be worth $14B in 2012. With close to 1.5M Americans being diagnosed with cancer every year, this market is expected to reach $20B by 2020. The recent FDA approval of Ipilimumab has demonstrated that immunotherapy can be successfully used for treating cancer.

Areas of Application

Immunotherapy

Stage of Development

Preclinical

Patent Information

PCT application ( PCT/US14/20299) pending Mar 4, 2014

Lead Investigator

Dr. Jedd Wolchok, MD/PhD, Laboratory Head, Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering

Contact Information

Yashodhara Dash, MBBS, PhD, MBA
Senior Manager, Technology Management and Commercialization
Tel: 646-888-1073
E-mail: dashy@mskcc.org
Stage of Development
Animal studies
Technology Types
Indications